Emerging role of colloidal drug delivery systems (cdds) in nsaid topical administration

Current Medicinal Chemistry

Volumn 20, Issue 14, 2013, Pages 1847-1857

  Puglia, Carmelo ^a   Tirendi, Giorgia Giusy ^a   Bonina, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Dermal; In vitro; In vivo; Nanotechnology; NSAIDs; Transdermal

Indexed keywords

ACECLOFENAC; CELECOXIB; CYCLODEXTRIN; DICLOFENAC; DRUG CARRIER; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LIPOSOME; NANOPARTICLE; NAPROXEN; NIMESULIDE; NIOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; TENOXICAM; VALDECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLLOIDAL DRUG DELIVERY SYSTEM; DILUTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; MICROEMULSION; NANOEMULSION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; STRATUM CORNEUM; TEMPERATURE; THERMODYNAMICS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84877967390     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320140004     Document Type: Article

References (72)

1. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New. Biol., 1971, 231(25), 232-235.
2. Roelofs, P.D.; Deyo, R.A.; Koes, B.W.; Scholten, R.J.; van Tulder M.W. Nonsteroidal anti-inflammatory drugs for low back pain: An updated Cochrane review. Spine, 2008, 33(16), 1766-1774.
3. Singh, G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am.J.Med., 1998, 105(1B), 31S-38S. (Pubitemid 28378015)
4. Haroutiunian, S.; Drennan, D.A.; Lipman, A.G. Topical NSAID therapy for musculoskeletal pain. Pain. Med., 2010, 11(4), 535-549.
5. Wissing, S.A.; Lippacher. A.; Müller, R.H. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J. Cosmet. Sci., 2001, 52, 313-324. (Pubitemid 33724124)
6. Jenning, V.; Gysler, A.; Schaffer-Korting, M.; Gohla, S.H. Vitamin A loaded solid lipid nanoparticles for topical use: Occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm., 2000, 49, 211-218. (Pubitemid 30229868)
7. Manjanna, K.M.; Shivakumar, B.; Pramod Kumar, T.M. Microencapsulation: An acclaimed novel drug-delivery system for NSAIDs in arthritis. Crit. Rev. Ther. Drug. Carrier. Syst., 2010, 27(6), 509-545.
8. Kreuter, J. Colloidal Drug Delivery Systems.; Marcel Dekker, Inc: New York, 1994.
9. Hoar, T.P.; Schulman, J.H. Transparent water-in-oil dispersions: The oleopathic hydro-micelle. Nature,1943, 152, 102-103.
10. Souto, E.B.; Doktorovova, S.; Boonme, P. Lipid-based colloidal systems (nanoparticles, microemulsions) for drug delivery to the skin: Materials and end-product formulations. J. Drug Del. Sci. Tech., 2011, 21(1), 43-54.
11. Anton, N.; Vandamme, T.F.; Nano-emulsions and microemulsions: Clarifications of the critical differences. Pharm. Res., 2011, 28(5), 978-985.
12. Friedman, D.I.; Schwarz, J.S.; Weisspapir, M. Submicron emulsion vehicle for enhanced transdermal delivery of steroidal and nonsteroidal antiinflammatory drugs. J. Pharm. Sci., 1995, 84(3), 324-329.
13. Rhee, Y.S.; Choi, J.G.; Park, E.S.; Chi, S.C. Transdermal delivery of ketoprofen using microemulsions. Int. J. Pharm., 2001, 228(1-2), 161-170.
14. Paolino, D.; Ventura, C.A.; Nistico, S.; Puglisi, G.; Fresta, M. Lecithin microemulsions for the topical administration of ketoprofen: Percutaneous adsorption through human skin and in vivo human skin tolerability. Int. J. Pharm., 2002, 244(1-2), 21-31. (Pubitemid 35245443)
15. Fischer, S.M.; Hawk, E.T.; Lubet, R.A. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev. Res., 2011, 4(11), 1728-1735.
16. Subramanian, N.; Ghosal, S.K.; Moulik, S. P. Topical delivery of celecoxib using microemulsion. Acta Pol. Pharm., 2004, 61(5), 335-341. (Pubitemid 40188845)
17. Kantarci, G.; Ozguney, I.; Karasulu, H.Y.; Guneri, T.; Basdemir, G. In vitro permeation of diclofenac sodium from novel microemulsion formulations through rabbit skin. Drug Dev. Res., 2005, 65(1), 17-25. (Pubitemid 41462892)
18. Kantarci, G.; Ozguney, I.; Karasulu, H.Y.; Arzik, S.; Guneri, T. Comparison of different water/oil microemulsions containing diclofenac sodium: Preparation, characterization, release rate, and skin irritation studies. AAPS Pharm.Sci.Tech., 2007, 8(4), E91.
19. Ambade, K.W.; Jadhav, S.L.; Gambhire, M.N.; Kurmi, S.D.; Kadam. V.J.; Jadhav, K.R. Formulation and evaluation of flurbiprofen microemulsion. Curr. Drug Del., 2008, 5(1), 32-41. (Pubitemid 351225632)
20. Alves, P.M.; Pohlmann, A.R.; Guterres, S. S. Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: Development and rheological characterization. Pharmazie, 2005, 60(12), 900-904. (Pubitemid 41820755)
21. Kim, B.S; Won, M.; Lee, K.M.; Kim, C.S. In vitro permeation studies of nanoemulsions containing ketoprofen as a model drug. Drug Del., 2008, 15(7), 465-469.
22. Sakeena, M. H. F.; Yam, M. F.; Elrashid, S. M.; Munavvar, A. S.; Azmin, M. N. Anti-inflammatory and analgesic effects of ketoprofen in palm oil esters nanoemulsion. J. Oleo Sci., 2010, 59(12), 667-671.
23. Abdulkarim, M.F.; Abdullah, G.Z.; Chitneni, M.; Salman, I.M.; Ameer, O.Z.; Yam, M.F.; Mahdi, E.S.; Sattar, M.A.; Basri, M.; Noor, A.M. Topical piroxicam in vitro release and in vivo antiinflammatory and analgesic effects from palm oil estersbased nanocream. Int. J. Nanomedicine, 2010, 5, 915-924.
24. Abdullah, G.Z.; Abdulkarim, M.F.; Salman, I.M.; Ameer, O.Z.; Yam, M.F.; Mutee, A.F.; Chitneni, M.; Mahdi, E.S.; Basri, M.; Sattar, M.A.; Noor, A. M. In vitro permeation and in vivo antiinflammatory and analgesic properties of nanoscaled emulsions containing ibuprofen for topical delivery. Int. J. Nanomedicine, 2011, 6, 387-396.
25. Shakeel, F.; Baboota, S.; Ahuja, A.; All, J.; Shafiq, S. Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation. Pharmazie, 2008, 63(8), 580-584.
26. Shakeel, F.; Ramadan, W.; Ahmed, M.A. Investigation of true nanoemulsions for transdermal potential of indomethacin: Characterization, rheological characteristics, and ex vivo skin permeation studies. J. Drug Target., 2009, 17(6), 435-441.
27. Shakeel, F.; Faisal, M.S. Nanoemulsion: A promising tool for solubility and dissolution enhancement of celecoxib. Pharm. Dev. Technol., 2010, 15(1), 53-56.
28. Schmid, M.H.; Korting, H.C. Therapeutic progress with topical liposome drugs for skin disease. Adv. Drug Del. Rev., 1996, 18(3), 335-342. (Pubitemid 26063307)
29. El Maghraby, G.M.; Barry, B.W.; Williams, A.C. Liposomes and skin: From drug delivery to model membranes. Eur. J. Pharm. Sci., 2008, 34(4-5), 203-222.
30. Kriwet, K.; Mueller-Goymann, C.C. Diclofenac release from phospholipid drug systems and permeation through excised human stratum corneum. Int. J. Pharm., 1995, 125(2), 231-242.
31. Canto, G.S; Dalmora, S. L.; Oliveira, A. G. Piroxicam encapsulated in liposomes: Characterization and in vivo evaluation of topical anti-inflammatory effect. Drug. Dev. Ind. Pharm., 1999, 25(12), 1235-1239.
32. Puglia, C.; Trombetta, D.; Venuti, V.; Saija, A.; Bonina, F. Evaluation of in-vivo topical anti-inflammatory activity of indometacin from liposomal vesicles. J. Pharm. Pharmacol., 2004, 56(10), 1225-1232. (Pubitemid 39368992)
33. Singh, B.; Mehta, G.; Kumar, R.; Bhatia, A.; Ahuja, N.; Katare, O.P. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr. Drug Deliv., 2005, 2(2), 143-153. (Pubitemid 40488624)
34. Ruozi, B.; Tosi, G.; Forni, F.; Vandelli, A.M. Ketorolac tromethamine liposomes: Encapsulation and release studies. J. Liposome Res., 2005, 15(3-4), 175-185. (Pubitemid 43062266)
35. Nagarsenker, M.S.; Amin, L.; Date, A.A. Potential of cyclodextrin complexation and liposomes in topical delivery of ketorolac: In vitro and in vivo evaluation. AAPS Pharm.Sci.Tech., 2008, 9(4), 1165-1170.
36. Chen, H.; Gao, J.; Wang, F.; Liang,W. Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. Drug Del., 2007, 14(4), 201-208. (Pubitemid 46752412)
37. Maestrelli, F.; Gonzalez-Rodriguez, M.L.; Rabasco, A.M.; Mura, P. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int. J. Pharm., 2006, 312(1-2), 53-60.
38. Puglia, C.; Bonina, F.; Rizza, L.; Cortesi, R.; Merlotti, E.; Drechsler, M.; Mariani, P.; Contado, C.; Ravani, L.; Esposito, E. Evaluation of percutaneous absorption of naproxen from different liposomal formulations. J. Pharm. Sci., 2010, 99(6), 2819-2829.
39. Manconi, M.; Caddeo, C.; Sinico, C.; Valenti, D.; Mostallino, M.C.; Biggio, G.; Fadda, A.M. Ex vivo skin delivery of diclofenac by transcutol containing liposomes and suggested mechanism of vesicle skin interaction. Eur. J. Pharm. Biopharm., 2011, 78(1), 27-35.
40. Bouwstra, J.A.; Hofland, H.E.J. Niosomes. In : Colloidal Drug Delivery Systems.; Kreuter, J. Ed; Marcel Dekker, Inc: New York, 1994; pp. 191-217.
41. Nasr, M.; Mansour, S.; Mortada, N.D.; Elshamy, A. A. Vesicular aceclofenac systems: A comparative study between liposomes and niosomes. J. Microencapsul., 2008, 25(7), 499-512.
42. Manosroi, A.; Jantrawut, P.; Manosroi, J. Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int. J. Pharm., 2008, 360(1-2), 156-163.
43. Alsarra, I.A. Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery. J. Microencapsul., 2009, 26(3), 272-278.
44. Hu, C.; Rhodes, D.G. Proniosomes: A Novel Drug Carrier Preparation. Int. J. Pharm., 1999, 185(1), 23-35. (Pubitemid 29333093)
45. Ammar, H.O.; Ghorab, M.; El-Nahhas, S.A.; Higazy, I.M. Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int. J. Pharm., 2011, 405(1-2), 142-152.
46. Zidan, A.S.; Mokhtar, M. Multivariate optimization of formulation variables influencing flurbiprofen proniosomes characteristics. J. Pharm. Sci., 2011, 100(6), 2212-2221.
47. Cevc, G.; Vierl, U. Nanotechnology and the transdermal route. J. Control. Release., 2011, 141(3), 277-299.
48. Cevc, G; Blume, G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim. Biophys. Acta, 2001, 1514(2), 191-205. (Pubitemid 32831008)
49. Cevc, G.; Mazgareanu, S.; Rother, M.; Vierl, U. Occlusion effect on transcutaneous NSAID delivery from conventional and carrierbased formulations. Int. J. Pharm., 2008, 359(1-2), 190-197.
50. Cevc, G.; Mazgareanu, S.; Rother, M. Preclinical characterization of NSAIDs in ultradeformable carriers or conventional topical gels. Int. J. Pharm., 2008, 360(1-2), 29-39.
51. Cevc, G.; Vierl, U.; Mazgareanu, S. Functional characterization of novel analgesic product based on self-regulating drug carriers. Int. J. Pharm., 2008, 360(1-2), 18-28.
52. El Zaafarany, G.M.; Awad, G.A.S.; Holayel, S.M.; Mortada, N.D. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int. J. Pharm., 2010, 397(1-2), 164-172.
53. Touitou, E.; Dayan, N.; Bergelson, L.; Godin, B.; Eliaz, M. Ethosomes -novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J. Control. Release, 2000, 65(3), 403-418. (Pubitemid 30122942)
54. Dave, V.; Kumar, D.; Lewis, S.; Paliwal, S. Ethosome for enhanced transdermal drug delivery of aceclofenac. Int. J. Drug Deliv.,2010, 2, 81-92.
55. Vijayakumar, M. R.; Abdul, Hasan Sathali, A.; Arun, K. Formulation and evaluation of diclofanac potassium ethosomes. Int. J. Pharm. Pharm. Sci., 2010, 2(4), 82-86.
56. Dalmora, M.E.; Oliveira, A.G. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int. J. Pharm., 1999, 184(2), 157-164. (Pubitemid 29317648)
57. Dalmora, M.E.; Dalmora, S.L.; Oliveira, A.G. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical antiinflammatory effect. Int. J. Pharm., 2001, 222(1), 45-55. (Pubitemid 32525787)
58. Doliwa, A.; Santoyo, S.; Ygartua, P. Influence of piroxicam: Hydroxypropyl-beta-cyclodextrin complexation on the in vitro permeation and skin retention of piroxicam. Skin Pharmacol. Appl. Skin Physiol., 2001, 14(2), 97-107. (Pubitemid 32375196)
59. Jug, M.; Becirevic-Lacan, M.; Kwokal, A. Cetina-Cizmek, B. Influence of cyclodextrin complexation on piroxicam gel formulations. Acta Pharm., 2005, 55(3), 223-236. (Pubitemid 41495267)
60. Cappello, B.; Di Maio, C.; Iervolino, M. Investigation on the Interaction of Bendazac with ?-, Hydroxypropyl-?-, and ?-Cyclodextrins. J. Incl. Phenom. Macro., 2002, 43(3-4), 251-257. (Pubitemid 38075756)
61. Aigner, Z.; Kezsmarki, A.; Kata, M.; Novak, C.; Eroes, I. Investigation of Tenoxicam and ?-Cyclodextrin Binary and Ternary Complexes. J. Incl. Phenom. Macro., 2002, 42(3-4), 227-233. (Pubitemid 38075795)
62. Maestrelli, F.; Gonzalez-Rodriguez, M. L.; Rabasco, A.M.; Mura, P. Preparation and characterization of liposomes encapsulating ketoprofen- cyclodextrin complexes for transdermal drug delivery. Int. J. Pharm., 2005, 298(1), 55-67. (Pubitemid 40834315)
63. Miyazaki, S.; Takahashi, A.; Kubo, W.; Bachynsky, J.; Loebenberg, R. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: In vitro release and in vivo skin penetration. J. Pharm. Pharm. Sci., 2003, 6(2), 240-245. (Pubitemid 37207230)
64. Puglia, C.; Bonina, F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin. Drug Deliv., 2012, 9(4), 429-441.
65. Muller, R.H., Radtke, M., Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242, 121-128.
66. Ricci, M.; Puglia, C.; Bonina, F.; Di Giovanni, C.; Giovagnoli, S.; Rossi, C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): In vitro and in vivo studies. J. Pharm. Sci., 2005, 94(5), 1149-1159. (Pubitemid 40780779)
67. Puglia, C.; Filosa, R.; Peduto, A.; de Caprariis, P.; Rizza, L.; Bonina, F.; Blasi, P. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS Pharm. Sci. Tech., 2006, 7(3), 64.
68. Puglia, C.; Blasi, P.; Rizza, L.; Schoubben, A.; Bonina, F.; Rossi, C.; Ricci, M. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int. J. Pharm., 2008, 357(1-2), 295-304.
69. Jain, S.K.; Chourasia, M.K.; Masuriha, R.; Soni, V.; Jain, A.; Jain, N.K.; Gupta, Y. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv., 2005, 12(4), 207-215. (Pubitemid 40981283)
70. Gonzalez-Mira, E.; Nikolic, S.; Garcia, M.L.; Egea, M.A.; Souto, E.B.; Calpena, A.C. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J. Pharm. Sci., 2011, 100(1), 242-51.
71. Joshi, M.; Patravale, V. Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. Drug Dev. Ind. Pharm., 2006, 32(8), 911-918. (Pubitemid 44359752)
72. Joshi, M.; Patravale, V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm., 2008, 346(1-2), 124-132. (Pubitemid 350110507)